54741_Image_jpeg.jpg
New Data Presented on Blood Volume at Annual Heart Failure Society Meeting Amid Call to Broadly Adopt Daxor’s Diagnostic Technology
September 18, 2019 08:00 ET | Daxor Corporation
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest
August 06, 2019 08:00 ET | Daxor Corporation
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019
May 31, 2019 08:00 ET | Daxor Corporation
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice
May 30, 2019 08:00 ET | Daxor Corporation
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019
March 15, 2019 08:30 ET | Daxor Corporation
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Showcase Reduction in Mortality and Hospital Readmissions with BVA-100® Guided-Care at the Annual Meeting of the American College of Cardiology Expo 2019
March 13, 2019 08:30 ET | Daxor Corporation
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018
March 04, 2019 08:30 ET | Daxor Corporation
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
Daxor Corporation Appoints Guido Manzo, Vice President of Sales
January 23, 2019 08:30 ET | Daxor Corporation
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the...
54741_Image_jpeg.jpg
New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension
November 13, 2018 08:30 ET | Daxor Corporation
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
54741_Image_jpeg.jpg
New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients
October 30, 2018 08:30 ET | Daxor Corporation
Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality NEW YORK , Oct. 30, 2018 (GLOBE...